Drugs & Aging

, Volume 29, Issue 5, pp 405–419 | Cite as

Dutasteride/Tamsulosin

In Benign Prostatic Hyperplasia
Adis Drug Profile

Abstract

The 5α-reductase inhibitor dutasteride and the α1-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate.

Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater extent than dutasteride or tamsulosin alone in men with BPH, moderate to severe LUTS and an increased risk of disease progression, according to the results of the randomized, double-blind, multinational CombAT trial. The mean change from baseline in the total International Prostate Symptom Score was significantly greater with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone after 2 years (primary endpoint) and 4 years of therapy.

After 4 years’ therapy in the CombAT trial, the time to first acute urinary retention or BPH-related surgery (primary endpoint) significantly favoured men with symptomatic BPH who were receiving dutasteride plus tamsulosin versus those receiving tamsulosin alone, with no significant difference between recipients of dutasteride plus tamsulosin and recipients of dutasteride alone.

In the CombAT trial, health-related quality of life and treatment satisfaction were improved to a significantly greater extent with dutasteride plus tamsulosin than with dutasteride or tamsulosin alone.

Combination therapy with oral dutasteride plus tamsulosin was generally well tolerated in patients with symptomatic BPH in the CombAT trial.

Notes

Acknowledgements

The manuscript was reviewed by: J. Barkin, Department of Surgery, University of Toronto, Toronto, ON, Canada; S. Gravas, Department of Urology, University of Thessaly, Larissa, Greece.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: management of benign prostatic hyperplasia (BPH) [online]. Available from URL: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bph [Accessed 2011 Nov 21]
  2. 2.
    Djavan B, Handl MJ, Dianat S. Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Pharmacother 2010; 11 (15): 2535–47PubMedCrossRefGoogle Scholar
  3. 3.
    Oelke M, Bachmann A, Descazeaud A, et al. The treatmtent of non-neurogenic male LUTS [online]. Available from URL: http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf [Accessed 2011 Nov 21]
  4. 4.
    National Institute for Health and Clinical Excellence. Lower urinary tract symptoms: the management of lower urinary tract symptoms in men. NICE clinical guideline 97 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/12984/48557/48557.pdf [Accessed 2011 Dec 8]
  5. 5.
    Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate. Clin Ther 2007 Jan; 29 (1): 17–25PubMedCrossRefGoogle Scholar
  6. 6.
    Gravas S, Oelke M. Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010 Feb; 28 (1): 9–15PubMedCrossRefGoogle Scholar
  7. 7.
    Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009; 4: 251–8PubMedGoogle Scholar
  8. 8.
    GlaxoSmithKline. Jalyn (dutasteride and tamsulosin hydrochloride) capsules: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_jalyn.pdf [Accessed 2011 Nov 17]
  9. 9.
    Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adhere 2011; 5: 483–90CrossRefGoogle Scholar
  10. 10.
    Naslund M, Eaddy MT, Hogue SL, et al. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin 2009 Nov; 25 (11): 2663–9PubMedGoogle Scholar
  11. 11.
    Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011 Mar; 107 (6): 876–80PubMedCrossRefGoogle Scholar
  12. 12.
    Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs 2008; 68 (4): 463–85PubMedCrossRefGoogle Scholar
  13. 13.
    Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004 May; 89 (5): 2179–84PubMedCrossRefGoogle Scholar
  14. 14.
    Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 Apr; 63 (4): 709–15PubMedCrossRefGoogle Scholar
  15. 15.
    Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10 (2): 149–54PubMedCrossRefGoogle Scholar
  16. 16.
    Rittmaster RS, Norman RW, Thomas LN, et al. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab 1996 Feb; 81 (2): 814–9PubMedCrossRefGoogle Scholar
  17. 17.
    Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57 (1): 123–31PubMedCrossRefGoogle Scholar
  18. 18.
    GlaxoSmithKline UK. Combodart(dutasteride/tamsulosin) 0.5 mg/0.4mg hard capsule: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/22943/SPC/Combodart+0.5+mg+++0.4+mg+hard+capsules/ [Accessed 2012 Apr 26]
  19. 19.
    Yamada S, Kato Y, Okura T, et al. Prediction of α1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull 2007 Jul; 30 (7): 1237–41PubMedCrossRefGoogle Scholar
  20. 20.
    Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002; 62 (1): 135–67PubMedCrossRefGoogle Scholar
  21. 21.
    Matsushima H, Kamimura H, Soeishi Y, et al. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos 1998 Mar; 26 (3): 240–5PubMedGoogle Scholar
  22. 22.
    van Hoogdalem EJ, Soeishi Y, Matsushima H, et al. Disposition of the selective α1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from inter-species scaling. J Pharm Sci 1997 Oct; 86 (10): 1156–61PubMedCrossRefGoogle Scholar
  23. 23.
    Kamimura H, Oishi S, Matsushima H, et al. Identification of cytochrome P450 isozymes involved in metabolism of the α1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998 Oct; 28 (10): 909–22PubMedCrossRefGoogle Scholar
  24. 24.
    Soeishi Y, Matsushima H, Watanabe T, et al. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica 1996 Jun; 26 (6): 637–45PubMedCrossRefGoogle Scholar
  25. 25.
    Wolzt M, Fabrizii V, Dorner GT, et al. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998 Jul; 54 (4): 367–73PubMedCrossRefGoogle Scholar
  26. 26.
    Miyazawa Y, Blum RA, Schentag JJ, et al. Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function. Curr Ther Res 2001 Sep; 62 (9): 603–21CrossRefGoogle Scholar
  27. 27.
    Clark R, Haberer L. The dual 5α-reductase inhibitor dutasteride is well tolerated and has no effect on the pharmacokinetic profiles of tamsulosin or terazosin when used in combination in healthy male volunteers [abstract no. 840]. Eur Urol Suppl 2005 Mar; 4 (3): 212CrossRefGoogle Scholar
  28. 28.
    Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 Feb; 179 (2): 616–21PubMedCrossRefGoogle Scholar
  29. 29.
    Siami P, Roehrborn CG, Barkin J, et al. Combination therapy with dutasteride and tamsulosin in men with moderateto-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007; 28 (6): 770–9PubMedCrossRefGoogle Scholar
  30. 30.
    Becher E, Roehrborn CG, Siami P, et al. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009; 12 (4): 369–74PubMedCrossRefGoogle Scholar
  31. 31.
    Montorsi F, Roehrborn C, Garcia-Penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int 2011; 107 (9): 1426–31PubMedCrossRefGoogle Scholar
  32. 32.
    Roehrborn CG, Siami P, Barkin J, et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55 (2): 461–71PubMedCrossRefGoogle Scholar
  33. 33.
    Chung B-H, Roehrborn CG, Siami P, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis 2009; 12 (2): 152–9PubMedCrossRefGoogle Scholar
  34. 34.
    Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 2011; 107 (6): 946–54PubMedCrossRefGoogle Scholar
  35. 35.
    Haillot O, Fraga A, Maciukiewicz P, et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis 2011 Dec; 14 (4): 302–6PubMedCrossRefGoogle Scholar
  36. 36.
    Tubaro A, Roehrborn CG, Barkin J, et al. Clinical outcomes after combination therapy with dutasteride and tamsulosin in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4 year results from the randomized, double-blind, CombAT trial [poster]. 25th Congress of the European Association of Urology; 2010 Apr 16–20; BarcelonaGoogle Scholar
  37. 37.
    Barkin J, Roehrborn CG, Siami P, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009; 103 (7): 919–26PubMedCrossRefGoogle Scholar
  38. 38.
    Montorsi F, Henkel T, Geboers A, et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010 Jul; 64 (8): 1042–51PubMedCrossRefGoogle Scholar
  39. 39.
    Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int 2012 Mar; 109 (5): 731–8PubMedCrossRefGoogle Scholar
  40. 40.
    Antoñanzas F, Brenes F, Molero JM, et al. Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain. Actas Urol Esp 2011; 35 (2): 65–71PubMedCrossRefGoogle Scholar
  41. 41.
    McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18; 349 (25): 2387–98PubMedCrossRefGoogle Scholar
  42. 42.
    Montlleó González M, Geiges G, Cicalese V, et al. Combination therapy with dutasteride plus tamsulosin reduces medical resource utilisation in men with benign prostatic hyperplasia: 4-year data from the CombAT study [abstract plus poster]. 25th Congress of the European Association of Urology; 2010 Apr 16–20; BarcelonaGoogle Scholar
  43. 43.
    Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011; 59 (2): 244–9PubMedCrossRefGoogle Scholar
  44. 44.
    Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. New Engl J Med 2010 Apr 1; 362 (13): 1192–202PubMedCrossRefGoogle Scholar
  45. 45.
    Andriole GL, Bostwick D, Brawley OW, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011 Jan; 185 (1): 126–31PubMedCrossRefGoogle Scholar
  46. 46.
    Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2012 Apr; 109 (8): 1162–9PubMedCrossRefGoogle Scholar
  47. 47.
    Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005 Sep; 174 (3): 877–81PubMedCrossRefGoogle Scholar
  48. 48.
    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 Jul 17; 349 (3): 215–24PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations